AstraZeneca Presentation

合集下载

Analysis_and_interpretation_of_financial_statements_I

Analysis_and_interpretation_of_financial_statements_I

Analysis and Interpretation of Financial Statements –Part I BEA3005 Lecture 7Dr Chen LimSource: Black, G. (2009) Introduction to Accounting and Finance, 2nded. Harlow: Pearson Education LtdConsolidated Income Statement 2010 2009 For the year ended 31 December2010 2009 $m $m £m £m 33,269 32,804 Turnover 28,392 28,368 (7,592)(7,380)20,800 20,988 (13,053)(9,592)AstraZeneca GSK Consolidated Statement of Financial Position 2010 2009 As at 31 December 2010 2009 $m $m Non-current assets£m £m 6,957 7,307 Property, plant and equipment 9,045 9,374 3,606 3,361 8,532 8,183 97 68 AstraZenecaGSKROCE vs. ROEROCE: Capital employed includes all capital contributions; hence use the all-inclusive profit measure (i.e. PBIT).Profit Measures (IS )RecipientsCapital Employed (SFP )Ratio Profit before interest and taxAll the following:ROCEAdd: Interest income Less: Interest expenses Debt holdersInterest-bearing debts Less: Preference dividends *Preference shareholdersPreference share capitalProfit before tax Less: Taxation Profit after taxLess: Preference dividends *Preference shareholders Preference share capital Less: Non-controlling interests **Minority shareholders *Total equity less NCI *Profit attributable to owners of the parentOrdinary shareholders Total equity (parent only)ROE* Preference dividends will appear as finance cost (if the preference share capital takes on the nature of a liability).** Only applies when group accounts are prepared and subsidiaries are not 100%-owned by the parent company.%4181008,8871,634.=×)=++118091429174528,392.,,)60.8%10014,809291=×+$48.59 £11.68 £12.26 CalculationConsolidated Statement of Cash Flows2010 2009 For the year ended 31 December2010 2009 $m $m £m £m Cash flow from operating activities8,631 9,545(775)(780)(1,834)(1,704) AstraZeneca GSK210 269 Proceeds from sale of intangible assets 126 356 (34)(31)Purchase of equity investments (279)(154)5 3 Proceeds from sale of equity investments 27 59(11)Payments made by subsidiaries to NCI– –(1,868)(4,013)62 43%520110011,49413,854.=×%912710014,759.=×66016,78711,068.=5609,918.=。

肿瘤免疫治疗相关不良反应管理

肿瘤免疫治疗相关不良反应管理

毒性管理 毒性监测
毒性分级管理原则,常见毒性管理,少见毒性管理
ICIs相关的毒性包括irAEs和输注反应,也包括可能发生的脱靶反应
毒性监测
附录:重启ICIs所致毒性,ICIs的毒性特征,中国人群的毒性数据
CSCO免疫检查点抑制剂相关的毒性管理指南. 2019 Proprietary and Confidential ©AstraZeneca 2018 • FOR INTERNAL USE ONLY
CSCO免P疫r检op查rie点ta抑ry制a剂nd相C关o的nf毒id性en管tia理l 指©A南s.t2ra0Z19eneca 2018 • FOR INTERNAL USE ONLY
肺毒性(肺炎)
是一种罕见但有致命威胁的严重不良事件。在所有肺炎病例中,72% 的患者为 1~2 级。与甲状腺炎和肝 炎等自限性免疫反应不同,大部分的免疫相关性肺炎需要激素或免疫抑制剂的治疗。
PropriethartytapndsC:/o/nfdidoenit.iaol ©rgAs/tr1aZ0e.n1e0ca12601/8j.•cFeOlRl.I2NT0E1R8NA.0L 9US.0E 3ON5LY
CTLA-4抗体的作用机制
1. 阻断竞争抑制: 阻断T细胞上CTLA-4与B7分子的结合,减少CTLA-4下游抑制信号,恢复CD28介导T的细胞活性,增加T细胞浸润 2. 耗竭Treg: 抗体还能与肿瘤微环境中巨噬细胞的Fcγ受体反应,介导细胞吞噬/杀伤作用(ADCC/ADCP),选择性消除肿瘤病变内的Treg细胞。 (该作Pro用prie依tary赖and于Con肿fide瘤ntia微l ©A环stra境Zen中eca表201达8 • FFOcRγIN受TER体NA的L US巨E O噬NL细Y 胞的存在)

阿斯利康

阿斯利康

我在阿斯利康的面试经历陈璐中国传媒大学2009-09-12 12:55:32astrazeneca, 世界5大制药集团之一,中国公司叫阿斯利康。

他们去年销售额180亿美金,研发经费达到35亿美金。

但是,我直到面试前一天才知道这一点。

可笑的是我一直以为这是一个职业中介,我将是他们的客户,他们得好好招待我,象对上帝一样. 我去了他们的网站,,一看这个域名就是一个职业中介嘛...面试结果一团糟糕,我估计是完蛋了。

第一轮面试就被淘汰,丢人呀! 不管如何,写出来,希望对大家有用。

早上9点,电话打来,先自我介绍,然后介绍参与interview的所有人,电话声音质量不是特别好,特别空洞,大概是用了那种三角型的多人电话会议系统的缘故。

对方说话不快,典型的学术英语,非常容易懂。

他说电话面试是面试的第一轮,他将问我6个关系到我背景的问题,不会有技术方面内容。

为了保证公平,每个候选人都会面对这同样的六个问题。

在面试结束后会有时间允许我问他们几个问题。

他们问的第一个问题是,请列出你现在的工作中你认为最重要的三样东西。

老实说,我是慌了手脚,我很紧张,所以回答得一团糟糕。

我回答我感兴趣,我喜欢研究,发现新的事务。

我还画蛇添足的回答因为我喜欢看到有我名字的文章发表在会议,期刊上。

我不知道我为什么要这样回答,极端愚蠢,我曾经想把这个interview录下来以便学习之用,我现在很庆幸没有这样做,我会尴尬致死的。

我说第二个重要的因素是与不同背景的人交流。

胡言乱语地解散了一通,我都记不起来我说来什么,肯定是我的大脑太过尴尬,不愿意记下了。

我只记得我刚讲完第二点对方就冷冰冰的说了一声ok,然后准备问第二个问题。

於是我不得不打断对方,说出来石破天惊第三点重要因素,我说,我会获得一个学位。

这是大实话呀,但我猜想对方并不愿意看到这一点,因为他又匆匆忙忙地说了一声ok,让我想起friends第4系列里面有一个长满大胡子的帅哥,老用这个强调说"ok".他们接着问第二个问题。

头孢哌酮钠舒巴坦钠与头孢唑肟分别联合NCPAP治疗对小儿重症肺炎病情控制及炎症因子的影响

头孢哌酮钠舒巴坦钠与头孢唑肟分别联合NCPAP治疗对小儿重症肺炎病情控制及炎症因子的影响

450 四川生理科学杂志 2021, 43(3)·临床研究·头孢哌酮钠舒巴坦钠与头孢唑肟分别联合NCPAP 治疗对小儿重症肺炎病情控制及炎症因子的影响袁胜男*(平顶山市妇幼保健院儿科,河南 平顶山 467000)摘要 目的:观察头孢哌酮钠舒巴坦钠与头孢唑肟分别联合经鼻高流量正压通气(Nasal continuous positive airway pressure ,NCPAP )治疗对小儿重症肺炎病情控制及炎症因子的影响。

方法:选取我院2018年7月至2020年7月收治的73例重症肺炎患儿为研究对象,依照完全随机化分组法将其分为对照组(n=36)和观察组(n=37)。

对照组和观察组患者分别在NCPAP 治疗基础上联合使用头孢唑肟50 mg•kg -1或头孢哌酮钠舒巴坦钠80 mg•kg -1静脉滴注进行治疗。

治疗1 w 后根据症状缓解程度评估患者病情控制率,并观察患者不良反应发生率,同时采用酶联免疫吸附试验(Enzyme linked immune-sorbent assay ,ELISA )法测定治疗前和治疗1 w 后血清白细胞介素-6(Interleukin-6,IL-6)、白细胞介素-8(Interleukin-8,IL-8)、肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)水平。

结果:治疗1 w 后,观察组患者病情控制率明显高于对照组 (P<0.05),而不良反应发生率无统计学差异(P>0.05);两组患者治疗1 w 后血清IL-6、IL-8、TNF-α水平较治疗前均明显降低 (P<0.05),且观察组明显低于对照组 (P<0.05)。

结论:头孢哌酮钠舒巴坦钠联合NCPAP 治疗对小儿重症肺炎疗效显著,能有效控制感染,降低炎症反应,具有较高临床应用价值。

关键词:头孢哌酮钠舒巴坦钠;头孢唑肟;重症肺炎儿童由于气道较为狭窄以及纤毛功能尚不完善致使感染后气道分泌物不易排除,因此小儿重症肺炎患儿若不及时治疗,常引发全身炎症反应、心力衰竭以及呼吸衰竭等严重并发症[1]。

阿斯利康形象宣传片AZ课件

阿斯利康形象宣传片AZ课件

文档仅供参考,不能作为科学依据,请勿模仿;如有不当之处,请联系本人改正。
与700个中国医疗机构紧密合作
Partnering with more than 700 medical institutions
文档仅供参考,不能作为科学依据,请勿模仿;如有不当之处,请联系本人改正。
关注弱势群体,积极开展各种公益活动
文档仅供参考,不能作为科学依据,请勿模仿;如有不当之处,请联系本人改正。
在心血管、消化、呼吸
Provides innovative treatment in areas of cardiovascular, gastrointestinal, respiratory,
文档仅供参考,不能作为科学依据,请勿模仿;如有不当之处,请联系本人改正。
文档仅供参考,不能作为科学依据,请勿模仿;如有不当之处,请联系本人改正。
12000名科研人员
12000名科研人员
12,000 R&D professionals
文档仅供参考,不能作为科学依据,请勿模仿;如有不当之处,请联系本人改正。
27个生产基地
27个生产基地
27 manufacturing sites
文档仅供参考,不能作为科学依据,请勿模仿;如有不当之处,请联系本人改正。
文档仅供参考,不能作为科学依据,请勿模仿;如有不当之处,请联系本人改正。
为了每一个灿烂的生命 为了每为个了健保康护的每生一命个,我生们命一的直健在康努力!
我们一直在努力!
Protecting every beautiful life is our mission
文档仅供参考,不能作为科学依据,请勿模仿;如有不当之处,请联系本人改正。
设立“红枫奖”以支持特殊教育

SYNERGY研究PPT优选课件

SYNERGY研究PPT优选课件

Median age (years)
68
Female sex (%)
34
Hypertension (%)
68
Diabetes (%)
29
Hypercholesterolemia (%) 58
Family history of CAD (%) 46
Myocardial infarction (%)
29
1 1.1 1.2
UFH Better
12 Countries. 467 Sites. 10,027 Patients.
Canada: 1616 USA: 5702
Europe: 5163
Belgium 355
Germany 456
Italy
72
Poland
381
Spain
412
Turkey
139
Presenters’ Disclosure Information: Relationships Related to this Presentation
Research Grants and/or Consultant fees:
Mahaffey: Aventis, AstraZeneca, Berlex, Lilly, Daiichi, Millennium, Merck, Schering-Plough, The Medicines Company
James J. Ferguson, M.D.
On behalf of the SYNERGY Investigators
The SYNERGY Trial
Superior Yield of the New strategy of Enoxaparin, Revascularization & GlYcoprotein IIb/IIIa Inhibitors

阿斯利康

2011年12月09日:阿斯利康收购中国注射抗生素制造商 Guangdong Beikang Pharmaceutical 。
2012年4月:阿斯利康于2012年4月6日完成其对广东倍康制药有限公司的收 购。
2012年2月48日:阿斯利康斥资12.6亿收购 Ardea 生物技术公司。 2012年7月.9日:阿斯利康和百时美施贵宝收购 Amylin。 2012年7月12日,阿斯利康(AstraZeneca)今天宣布,已完成 Link Medicine 公司(Link Medicine Corporation)神经科学资产的收购。 2013年8月.02日:阿斯利康拟收购韩国 Celltrion 拓展仿制药业务。 2013年6月24日瑞典制药业巨头阿斯利康宣布将以总额为11.5亿美元价格收 购美国加州一家医疗器材公司。 2013年7月18日:阿斯利康宣布,已完成对 Omthera 制药的收购,该公司总 部位于新泽西州普林斯顿,专注于开发及商业化新疗法,用于血脂异常 (dyslipidemia)的治疗。 2013.7月31日,韩国生物制品制造商 Celltrion 股价在首尔交易所创纪录的 上涨15%涨停至65400韩元,是该公司自2005年开始股票交易以来的最高股价,同
高胆固醇血症
三、收购公司 2005.年12月30日:阿斯利康计划出资2.10亿美元收购 KuDOS 公司。 2005年12月31日:阿斯利康2.10亿美元收购 KuDOS 制药公司。 2006年5月15日:英国-瑞典制药商阿斯利康(AstraZeneca)(AZN)宣布,已同
意收购剑挢抗体科技公司(CATG)。 2007年4月23日:阿斯利康以156亿美元收购 MedImmune 公司,制造了年度最
阿斯利康坚信要成功实现阿斯利康的战略重点,最重要的是要成为负责任的 企业。这是阿斯建立良好声誉的基础。阿斯利康在成熟市场和新兴市场上进行的 所有活动——无论是内部活动还是外包活动,都考虑到发展的可持续性并且遵循 高尚的道德准则,对此阿斯利康的股东需要抱有信心。成为受欢迎和值得信任的 合作伙伴,重新塑造阿斯利康的市场和增加阿斯利康的外在化,是阿斯利康成功 的关键。

astrazereca译文

astrazereca译文主题:阿斯利康(AstraZeneca)疫苗原文:AstraZeneca, a British-Swedish multinational pharmaceutical company, developed and produced a vaccine against COVID-19. The vaccine is based on a weakened version of a common cold virus. This virus is genetically modified to include the spike protein found on the surface of the SARS-CoV-2 virus. The vaccine is administered as two doses, several weeks apart.The AstraZeneca vaccine has been authorized for emergency use by several countries, including the United Kingdom, India, and Brazil. However, some countries have suspended its use due to concerns about possible side effects.Regardless of the controversy surrounding the vaccine, AstraZeneca continues to produce and distribute its vaccine to help fight the global pandemic.译文:阿斯利康是一家总部位于英国和瑞典的跨国制药公司,它研发并生产了一种针对COVID-19的疫苗。

The history of the development of AstraZeneca

The history of the development of AstraZeneca AstraZeneca plc is a British-Swedish multinational pharmaceutical and biologics company headquartered in London, United Kingdom. It is the world's seventh-largest pharmaceutical company measured by 2009 prescription drug sales (after Pfizer, Novartis, Sanofi, and GlaxoSmithKline) and has operations in over 100 countries. It has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Sweden-based Astra AB and the UK-based Zeneca Group.AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It had a market capitalisation of approximately £39.5 billion as of 23 December 2011, the tenth-largest of any company with a primary listing on the London Stock Exchange. It has secondary listings on the New York Stock Exchange and the OMX exchange.Astra AB was founded in 1913 in Södertälje, Sweden, by 400 doctors and apothecaries. In 1993 the British chemicals company ICI demerged its pharmaceuticals businesses and its agrochemicals and specialties businesses, to form Zeneca Group plc,. Finally, in 1999 Astra and Zeneca Group merged to form AstraZeneca plc. In 1999, AstraZeneca identified the "Fairfax-plus" site in North Wilmington, Delaware as the new location for the recently merged pharmaceutical company's US headquarters.On 3 January 2004 Dr Robert Nolan, the former director of AstraZeneca, formed the management team of ZI Medical.In 2005, the company announced that it had become a Diamond Member of the Pennsylvania Bio commerce organisation. It also acquired KuDOS Pharmaceuticals, a UK biotech company, for £120m and entered into an anti-cancer collaboration agreement with Astex.In 2006, following a collaborative relationship begun in 2004, AstraZeneca acquired Cambridge Antibody Technology for £702 million.In February 2007, AstraZeneca agreed to buy Arrow Therapeutics, a company focused on the discovery and development of anti-viral therapies, for $150 million. AstraZeneca's pipeline, and "patent cliff", was the subject of much speculation in April 2007 leading to pipeline-boosting collaboration and acquisition activities. A few days later AstraZeneca acquired American company MedImmune for about $15.2 billion to gain flu vaccines and an anti-viral treatment for infants; AstraZeneca subsequently consolidated all of its biologics operations into a dedicated biologics division called MedImmune.In 2011, AstraZeneca acquired Guangdong BeiKang Pharmaceutical Company, a Chinese generics business.In February 2012, AstraZeneca and Amgen announced collaboration on treatments for inflammatory diseases. Then in April 2012, AstraZeneca acquired Ardea Biosciences, another biotechnology company, for $1.26 billion.In June 2012, AstraZeneca and Bristol-Myers Squibb announced a two-stage deal for the joint acquisition of the biotechnology company Amylin Pharmaceuticals. It was agreed that Bristol-Myers Squibb would acquire Amylin for $5.3 billion in cash and the assumption of $1.7 billion in debt, with AstraZeneca then paying $3.4 billion in cash to Bristol-Myers Squibb, and Amylin being folded into an existing diabetes joint-venture between AstraZeneca and Bristol-Myers Squibb.In March 2013, AstraZeneca said it will cut 2,300 jobs as part of a restructuring of its business.In October 2013, AstraZeneca announced it would acquire biotech company Spirogen for around $440 million.以上内容来自wikipedia,下面是我用谷歌网页翻译的上面的内容,你对照着理解吧,虽然不是很准确,但是大致的意思还是可以的,你要是需要翻译的话,也可以根据上面的英文把下面的翻译修改一下,语句改通顺了就可以。

分娩镇痛对产后抑郁症发生的影响


analgesia when
their cervical
in 2—3 cm.VAS
was
maintained
below 3 after the analgesia.Parturients days after the
was
completed Edinburgh
of depressiosion recorded.Results in VD
and uplifts
on
inflammation and
coagulability[J].Psycho・
l;

一山雌小


physiology,2007,44(1):154-160. [5]Ding T,Wang DX,Qu
associated with

毗忆鼋_
[2] m皿∥蹦 [3]

Y,et
Effect of labor analgesia
on
development of postpartum depression
Su
Yue,Sun
Jie,Xu Mingjun,
University
Che Xiangming.Department
of
Anesthesiology,Obstetric
and
唧删一小 黧羔裟譬裟黑~砸慕 ‰舢 ~c;;; Ⅲ二詈 纛 =i||;氍= 一~一~一一~一


|l啦

~雌l;


耻儿
(收稿日期:2014.03.20)
(本文编辑:刘玉华)
・读者・作者・编者・
论著摘要及关键词的要求
论著中文、英文摘要由4个部分组成,包括目的(Objective)、方法(Methods)、结果(Results)和结论(Conclusion)。采用第 三人称撰写,不列图表,不引用文献,不加评论和解释。除了公知公认者外,摘要中首次出现的缩略语、代号等须注明全称或 加以说明。中文摘要一般要求250~400个汉字;英文摘要与中文摘要原则上相对应,鉴于国际交流的需要,其内容可更详细。 每篇论文要求标引2~5个关键词。中文、英文关键词应一致。要求采用美国国立医学图书馆编辑出版的最新版《医学主 题词表(MeSH)》内所列的词,可通过http://www.nebi.nlm.nih.gov/entrez/query.fcgi?db=mesh查询。如果最新版MeSH中尚无
  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Assessment Center
Assessment Center (AC) is to be adopted for the recruitment of Supervisor & above.
Approach Interview Group Exercise
Motivation Communicat ion Decision making Work with people Innovation
2nd INT ERVIE W 1st INT ERVIE W TE LEPHONE SCREEN
CV SCREENING CANDIDAT ES Dat abase S ear ch Advertise Oth er Agencies Resou rcing In itiatives INNO VE X JO B B RIEF CUSTOME R BRIE F
Territory
*Tier I *Tier II *Tier III
Resourcing Organization Structure
Opeartion Director
Resourcing Manager China
Recruitment Assistant 1 Human Resource Assistant
Motivation Key Interpersonal Competence skills to be assessed Judgement Work with people Develop others Customer focus Planning Innovation
Years
0
10
20
30
COSTS
Outsourcing means you can manage costs more efficiently and transparently
Why Outsource?
36
Flexibility in contract Motivated staff
41
33
Territory Vacancy Management
Health Management Services
Sales Management Training & Development
Recruitment
Sales force “Healthcheck”
The Benefits Of Outsourcing
Background Information Personal Behavior Competence Profile
Recruitment Activity -1
Telephone Screening
Background Information:
* Education
* Work Experience * Job related knowledge
More effective selling means we can gain bigger market share more quickly
Faster trials mean we can Reduce time to launch
SALES
Flexibility means maintain market position longer
Recruitment Activity - 2
1st Interview
Personal Behavior:
*
Appearance
* Communication Competence * Language Capability
* Interests * Job performance
Recruitment Activity - 3
Key Issues for Provision of Recruitment Timelines
Based on:
* * * *
Team Size
Job Specification Territory
Extent of Operational Control
Breadth of Recruitment in China
76
Concentration on core business
80
0
10
20
30
40
50
60
70
% Survey Respondents
Source: KPMG survey 2000
Flexibility to Meet Peaks
Without outsourcing
Resource need/level In House With outsourcing
Contract sign off
•Database Search
• Position job specification • Territory • Size
Customer to provide
•Advertise •Other Agencies •Resourcing Initiatives CV Collection
3 weeks 2 weeks
CV Screening Telephone Screening 1st Interview 2nd Interview Job Offer
Profile Brief Marching
Around 10 screened CVs for 1 position Around 5 Tel-screened CVs for 1 position Around 2-2.5 1st interviewed CVs for 1 position Customer Involvement?
Presentation
Decision making Communication Organising Work with people
In-tray Exercise
Planning Judgement Commercial awareness Work with people
Commercialisation
Innovex
Building sales teams that sell drugs to doctors on behalf of Pharma companies
18,000 people 7,400 MR’s 31 locations
Information Technology Platform
Part II Innovex Competence Based Recruitment
Key Issues-Recruitment
JOB OFFER . . ..the process can be m odified to ac hie ve specific custom er objectiv es.
2nd Interview Competency Profile:
*
Motivation
* Interpersonal Skills * Learning / Development Skills * Decision Making / Judgement * Customer Focus * Working with People * Planning & organization * Innovation
CONTENT
Part I : Innovex In China
Part II:
Innovex Competence Based Recruitment
Part III: Innovex Training Part IV: Innovex Shadow Sales Team
Part I
Innovex in China
Time
Resource need/ level
Outsourced In House
Time
Key Benefits of Outsourcing
Increases strategic flexibility Customers can concentrate on core business and the issues of tomorrow. Gain access to best in class service providers and their skills. Enables fundamental change in business and processes. Creates competitive differentiation through innovation. Reduces costs (through economy of scale) and provides cost transparencycontrol. Flexibility for future workload planning. Managing new product responsibilities Process management Strategic direction
INNO VE X’ S rec ruitment p roc ess:Develope d ove r th e last 20 years this process ensures we select only th e best re presentatives . . .
Recruitment Activity
China Experience
Projects Completed or Ongoing in China to Date:
Customer
相关文档
最新文档